Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe to give multiple doses of CPI-1189 to
HIV-infected, otherwise healthy, males. The study will also look at how CPI-1189 affects the
levels of HIV, T cells (cells in the body that help fight infection), and three anti-HIV
drugs (zidovudine, lamivudine, and indinavir) in the blood.
Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to losses of
memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.